Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Tesla, Spirit Airlines and CVS Health rise premarket; Nvidia falls

Published 2024-11-18, 08:18 a/m
F
-
NVDA
-
CVS
-
TSLA
-
SAVEQ
-
SMCI
-
SNDX
-

Investing.com -- US stock futures traded in a mixed fashion Monday, with traders awaiting more corporate earnings as well as speeches from a number of Fed officials.

Here are some of the biggest premarket US stock movers today:

  • Tesla (NASDAQ:TSLA) stock surged 5.9% following reports from Bloomberg that the incoming Trump administration will establish a federal framework for fully self-driving vehicles and make it a top priority for the Department of Transportation.

  • Nvidia (NASDAQ:NVDA) stock fell 3.4% amid doubts over the strength of sales of its new Blackwell chips, ahead of the chipmaker’s quarterly earnings on Wednesday.

  • Spirit Airlines (NYSE:SAVE) stock rose 2.8% after the budget carrier filed for bankruptcy protection after years of mounting losses, stating that it has reached a prearranged deal with its bondholders to help it through the bankruptcy, which it expects to exit in the first quarter of next year.

  • Ford (NYSE:F) stock rose 0.3% despite the US auto safety regulator stating it had initiated a recall query into about 112,567 of the auto giant’s SUVs over an issue with seat belt retractors.

  • CVS Health (NYSE:CVS) stock rose 1.9% after the pharmacy chain said it would add four new members to its board in an agreement with Glenview Capital Management, including the hedge fund's chief executive Larry Robbins.

  • Super Micro Computer (NASDAQ:SMCI) stock rose over 10% as investors awaited a planned filing that would allow the server maker to avoid being delisted

  • Astera Labs (NASDAQ:ALAB) stock rose 3% after Citi initiated coverage of the semiconductor stock with a ‘buy’ rating, saying the shares provide artificial intelligence investors with a unique opportunity.

  • Syndax Pharmaceuticals (NASDAQ:SNDX) stock rose 6% after the FDA approved its Revuforj drug for the treatment of certain leukemia patients.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.